• Completed $146m Entitlement Offer, extending cash runway to >$200m
• Progressed third drug program into human trials for polycystic kidney disease
• Preparing for multiple near-term human efficacy readouts, starting in May 2025

PYC Therapeutics, a clinical-stage biotechnology company, has provided a shareholder update on its progress in the first quarter of 2025. The company continues to advance towards its 48-month objective of becoming a commercial-stage drug developer, with key achievements in Q1 2025 including the completion of a $146m Entitlement Offer that has extended PYC's cash runway to over $200m. This funding will support the progression of the company's pipeline of three clinical-stage, first-in-class drug candidates, with a focus on generating clinical proof-of-concept for each program. PYC has also advanced its third drug development program into human trials, targeting the major unmet need of polycystic kidney disease. The company is now funded into 2027 and is preparing for multiple near-term human efficacy readouts, starting with the presentation of data from its ongoing Phase 1/2 studies in Retinitis Pigmentosa in early May 2025. This transition to a multi-asset, late clinical-stage company positions PYC well for an improvement in life sciences market conditions as it progresses towards its goal of becoming a fully integrated, commercial-stage drug discovery and development company.

PYC Therapeutics is now funded into 2027 and is preparing for multiple near-term human efficacy readouts within its pipeline of first-in-class drug candidates, starting with data from its ongoing Phase 1/2 studies in Retinitis Pigmentosa in early May 2025.